Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06824779 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Impact of FLU Vaccination on Nasal Resident Memory Immune Responses and Peripheral Respiratory-tropic Memory Immune Responses

Study acronym: MUCOVAC_2
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Primary completion date changed from estimate of Mar 2026 to Dec 19, 2025 · Site details revisedv4 Show 2 more changesShow less
    • Primary completion date changed from estimate of Mar 2026 to Dec 19, 2025
    • Site details revised
  2. Trial status: Not Yet Recruiting to Recruiting Primary and study completion dates: Feb 2026 to Mar 2026 · Start date changed from estimate of Oct 2025 to Dec 5, 2025 · Site details revisedv3 Show 3 more changesShow less
    • Primary and study completion dates: Feb 2026 to Mar 2026
    • Start date changed from estimate of Oct 2025 to Dec 5, 2025
    • Site details revised
  3. Interventions: Biological samples (Biological) to Biological samples (Biological), Flu Vaccine (Drug) Site contact updatedv2 Show 1 more changeShow less
    • Site contact updated
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Mucosal sites, such as respiratory mucosa, are the primary entry points entry points for pathogens. However, clinical evaluation of vaccines against respiratory respiratory pathogens is currently based primarily on analysis of systemic, i.e. peripheral antibody and cellular responses. These measurements give little indication of the immune responses in respiratory tissues tissues, even though the latter are essential for protection against infection. Protective immune responses in mucous membranes, including respiratory including respiratory tissues, rely on secretory IgA to neutralize pathogens neutralization of pathogens on the mucosal surface, as well as the development of the development of cellular responses, notably those from T (Trm) and B (Brm) lymphocytes. Preclinical studies and a few human studies have demonstrated that Trm are a crucial element mucosal protection against viral and bacterial infections. In fact it has been shown that resident memory lymphocytes, including Trm, are able to able to reside in nasal, pulmonary, intestinal, genital and skin mucosa and skin after infection.
Trial Details
NCT Number NCT06824779
Lead Sponsor Centre Hospitalier Universitaire de Saint Etienne
Collaborators: Sanofi Pasteur, a Sanofi Company
Conditions Volunteers, Flu Vaccine
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov